Pathophysiology, subtypes, and treatments of adult-onset Still's disease: An update;Données actualisées sur la physiopathologie, les phénotypes et les traitements de la maladie de Still de l'adulte

Revue de Medecine Interne

Volumn 36, Issue 5, 2015, Pages 319-327

  Gerfaud Valentin, M ^a,b,c   Seve P ^a,b,c   Hot, A ^b,c,d   Broussolle, C ^a,b,c   Jamilloux, Y ^a,e,f  

^a CROIX ROUSSE HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITÉ DE LYON   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Adult onset Still's disease; Autoinflammatory syndrome; Interleukin 1; Interleukin 6

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 6 BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT ONSET STILL DISEASE; DRUG EFFICACY; HEMOPHAGOCYTIC SYNDROME; HIGH RISK POPULATION; HUMAN; PATHOPHYSIOLOGY; SHORT SURVEY; TREATMENT OUTCOME; ADULT; CLASSIFICATION; DISEASE COURSE; RISK FACTOR; STILL'S DISEASE, ADULT-ONSET;

ADULT; DISEASE PROGRESSION; HUMANS; RISK FACTORS; STILL'S DISEASE, ADULT-ONSET;

EID: 84928644983     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2014.10.365     Document Type: Short Survey

References (110)

1. Bywaters E.G. Still's disease in the adult. Ann Rheum Dis 1971, 30:121-133.
2. Magadur-Joly G., Billaud E., Barrier J.H., Pennec Y.L., Masson C., Renou P., et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 1995, 54:587-590.
3. Wakai K., Ohta A., Tamakoshi A., Ohno Y., Kawamura T., Aoki R., et al. Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol 1997, 7:221-225.
4. Evensen K.J., Nossent H.C. Epidemiology and outcome of adult-onset Still's disease in Northern Norway. Scand J Rheumatol 2006, 35:48-51.
5. Pay S., Türkçapar N., Kalyoncu M., Simşek I., Beyan E., Ertenli I., et al. A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol 2006, 25:639-644.
6. Gerfaud-Valentin M., Maucort-Boulch D., Hot A., Iwaz J., Ninet J., Durieu I., et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57patients. Medicine (Baltimore) 2014, 93:91-99.
7. Sampalis J.S., Esdaile J.M., Medsger T.A., Partridge A.J., Yeadon C., Senécal J.L., et al. A controlled study of the long-term prognosis of adult Still's disease. Am J Med 1995, 98:384-388.
8. Cagatay Y., Gul A., Cagatay A., Kamali S., Karadeniz A., Inanc M., et al. Adult-onset Still's disease. Int J Clin Pract 2009, 63:1050-1055.
9. Chen P.D., Yu S.L., Chen S., Weng X.H. Retrospective study of 61patients with adult-onset Still's disease admitted with fever of unknown origin in China. Clin Rheumatol 2012, 31:175-181.
10. Colina M., Zucchini W., Ciancio G., Orzincolo C., Trotta F., Govoni M. The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76Italian patients. Semin Arthritis Rheum 2011, 41:279-285.
11. Pouchot J., Sampalis J.S., Beaudet F., Carette S., Décary F., Salusinsky-Sternbach M., et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 1991, 70:118-136.
12. Terkeltaub R., Esdaile J., Décary F., Harth M., Lister J., Lapointe N. HLA-Bw35 and prognosis in adult Still's disease. Arthritis Rheum 1981, 12:1469-1472.
13. Wouters J.M., Reekers P., van de Putte L.B. Adult-onset Still's disease. Disease course and HLA associations. Arthritis Rheum 1986, 29:415-418.
14. Fujii T., Nojima T., Yasuoka H., Satoh S., Nakamura K., Kuwana M., et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (Oxford) 2001, 40:1398-1404.
15. Joung C.I., Lee H.S., Lee S.W., Kim C.G., Song Y.H., Jun J.B., et al. Association between HLA-DR B1 and clinical features of adult onset Still's disease in Korea. Clin Exp Rheumatol 2003, 21:489-492.
16. Chen D.Y., Chen Y.M., Chen H.H., Hsieh C.W., Lin C.C., Lan J.L. Functional association of interleukin 18 gene-607 (C/A) promoter polymorphisms with disease course in Chinese patients with adult-onset Still's disease. J Rheumatol 2009, 36:2284-2289.
17. Wang F.F., Huang X.F., Shen N., Leng L., Bucala R., Chen S.L., et al. A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still's disease. Arthritis Res Ther 2013, 15:R65.
18. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102:1369-1376.
19. Riolet J. Wissler-Fanconi syndrome. Rev Rhum Mal Osteoartic 1964, 31:388-397.
20. Wouters J.M., van der Veen J., van de Putte L.B., de Rooij D.J. Adult onset Still's disease and viral infections. Ann Rheum Dis 1988, 47:764-767.
21. Escudero F.J., Len O., Falcó V., de Sevilla T.F., Sellas A. Rubella infection in adult onset Still's disease. Ann Rheum Dis 2000, 59:493.
22. Perez C., Artola V. Adult Still's disease associated with Mycoplasma pneumoniae infection. Clin Infect Dis 2001, 32:105-106.
23. Kádár J., Petrovicz E. Adult-onset Still's disease. Best Pract Res Clin Rheumatol 2004, 18:663-676.
24. Liozon E., Ly K.H., Vidal-Cathala E., Fauchais A.-L. Adult-onset Still's disease as a manifestation of malignancy: report of a patient with melanoma and literature review. Rev Med Interne 2014, 35:60-64.
25. Michot J.M., Hié M., Galicier L., Lambotte O., Michel M., Bloch-Queyrat C., et al. Hemophagocytic lymphohistiocytosis. Rev Med Interne 2013, 34:85-93.
26. Matsui K., Tsuchida T., Hiroishi K., Tominaga K., Hayashi N., Hada T., et al. High serum level of macrophage-colony stimulating factor (M-CSF) in adult-onset Still's disease. Rheumatology (Oxford) 1999, 38:477-478.
27. Hoshino T., Ohta A., Yang D., Kawamoto M., Kikuchi M., Inoue Y., et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol 1998, 25:396-398.
28. Jung S.Y., Park Y.B., Ha Y.J., Lee K.H., Lee S.K. Serum calprotectin as a marker for disease activity and severity in adult-onset Still's disease. J Rheumatol 2010, 37:1029-1034.
29. Zou Y.Q., Lu L.J., Li S.J., Zeng T., Wang X.D., Bao C.D., et al. The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still's disease. Clin Biochem 2008, 41:519-524.
30. Chen D.Y., Lan J.L., Lin F.J., Hsieh T.Y. Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still's disease. Arthritis Rheum 2005, 53:320-327.
31. Hot A., Toh M.L., Coppéré B., Perard L., Girard-Madoux M.H., Mausservey C., et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8patients. Medicine (Baltimore) 2010, 89:37-46.
32. Lee S.J., Cho Y.N., Kim T.J., Park S.C., Park D.J., Jin H.M., et al. Natural killer T cell deficiency in active adult-onset Still's disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells. Arthritis Rheum 2012, 64:2868-2877.
33. Wulffraat N.M., Rijkers G.T., Elst E., Brooimans R., Kuis W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford) 2003, 42:375-379.
34. Min J.K., Cho C.S., Kim H.Y., Oh E.J. Bone marrow findings in patients with adult Still's disease. Scand J Rheumatol 2003, 32:119-121.
35. Komiya A., Matsui T., Nogi S., Iwata K., Futami H., Takaoka H., et al. Neutrophil CD64 is upregulated in patients with active adult-onset Still's disease. Scand J Rheumatol 2012, 41:156-158.
36. Samson M., Lakomy D., Audia S., Bonnotte B. T(H)17 lymphocytes: induction, phenotype, functions, and implications in human disease and therapy. Rev Med Interne 2011, 32:292-301.
37. Antoniou K.M., Margaritopoulos G.A., Giannarakis I., Choulaki C., Fountoulakis N., Siafakas N.M., et al. Adult onset Still's Disease: a case report with a rare clinical manifestation and pathophysiological correlations. Case Rep Med 2013, 2013:981232. [Epub 2013 Jan 17]. 10.1155/2013/981232.
38. Jamilloux Y., Sève P., Henry T. Inflammasomes in human diseases. Rev Med Interne 2014, 35:730-741.
39. Chen D.Y., Lin C.C., Chen Y.M., Lan J.L., Hung W.T., Chen H.H., et al. Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still's disease. Arthritis Res Ther 2013, 15:R39.
40. Rau M., Schiller M., Krienke S., Heyder P., Lorenz H., Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis. J Rheumatol 2010, 37:2369-2376.
41. Chen D.Y., Lan J.L., Lin F.J., Hsieh T.Y. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 2004, 31:2189-2198.
42. Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005, 201:1479-1486.
43. Lequerré T., Quartier P., Rosellini D., Alaoui F., De Bandt M., Mejjad O., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008, 67:302-308.
44. Carroll H.P., Paunovic V., Gadina M. Signalling, inflammation and arthritis: crossed signals: the role of interleukin-15 and -18 in autoimmunity. Rheumatology (Oxford) 2008, 47:1269-1277.
45. Rooney T., Murphy E., Benito M., Roux-Lombard P., FitzGerald O., Dayer J.-M., et al. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis 2004, 63:1393-1398.
46. Conigliaro P., Priori R., Bombardieri M., Alessandri C., Barone F., Pitzalis C., et al. Lymph node IL-18 expression in adult-onset Still's disease. Ann Rheum Dis 2009, 68:442-443.
47. Priori R., Barone F., Alessandri C., Colafrancesco S., McInnes I.B., Pitzalis C., et al. Markedly increased IL-18 liver expression in adult-onset Still's disease-related hepatitis. Rheumatology (Oxford) 2011, 50:776-780.
48. Kawaguchi Y., Terajima H., Harigai M., Hara M., Kamatani N. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum 2001, 44:1716-1717.
49. Scheinberg M.A., Chapira E., Fernandes M.L., Hubscher O. Interleukin 6: a possible marker of disease activity in adult onset Still's disease. Clin Exp Rheumatol 1996, 14:653-655.
50. Choi J.H., Suh C.H., Lee Y.M., Suh Y.J., Lee S.K., Kim S.S., et al. Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 2003, 30:2422-2427.
51. Chen D.Y., Lan J.L., Lin F.J., Hsieh T.Y., Wen M.C. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis 2004, 63:1300-1306.
52. Chen D.Y., Chen Y.M., Lan J.L., Lin C.C., Chen H.H., Hsieh C.W. Potential role of Th17 cells in the pathogenesis of adult-onset Still's disease. Rheumatology (Oxford) 2010, 49:2305-2312.
53. Chen D.Y., Chen Y.M., Chen H.H., Hsieh C.W., Lin C.C., Lan J.L. The associations of circulating CD4+CD25 high regulatory T cells and TGF-β with disease activity and clinical course in patients with adult-onset Still's disease. Connect Tissue Res 2010, 51:370-377.
54. Gerfaud-Valentin M., Jamilloux Y., Iwaz J., Sève P. Adult-onset Still's disease. Autoimmun Rev 2014, 13:708-722.
55. Crispín J.C., Martínez-Baños D., Alcocer-Varela J. Adult-onset Still disease as the cause of fever of unknown origin. Medicine (Baltimore) 2005, 84:331-337.
56. Robine A., Hot A., Maucort-Boulch D., Iwaz J., Broussolle C., Sève P. Fever of unknown origin in the 2000s: evaluation of 103cases over eleven years. Presse Med 2014, 43:e233-e240. [Epub 2014 Jun 28]. 10.1016/j.lpm.2014.02.026.
57. Cozzi A., Papagrigoraki A., Biasi D., Colato C., Girolomoni G. Cutaneous manifestations of adult-onset Still's disease: a case report and review of literature. Clin Rheumatol 2014, [Epub ahead of print]. 10.1007/s10067-014-2614-2.
58. Ota T., Higashi S., Suzuki H., Eto S. Increased serum ferritin levels in adult Still's disease. Lancet 1987, 1:562-563.
59. Fautrel B. Ferritin levels in adult Still's disease: any sugar?. Joint Bone Spine 2002, 69:355-357.
60. Fautrel B., Le Moël G., Saint-Marcoux B., Taupin P., Vignes S., Rozenberg S., et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol 2001, 28:322-329.
61. Zeng T., Zou Y.Q., Wu M.F., Yang C.D. Clinical features and prognosis of adult-onset still's disease: 61cases from China. J Rheumatol 2009, 36:1026-1031.
62. Lee S.W., Park Y.B., Song J.S., Lee S.K. The mid-range of the adjusted level of ferritin can predict the chronic course in patients with adult onset Still's disease. J Rheumatol 2009, 36:156-162.
63. Rosário C., Zandman-Goddard G., Meyron-Holtz E.G., D'Cruz D.P., Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 2013, 11:185.
64. Fardet L., Coppo P., Kettaneh A., Dehoux M., Cabane J., Lambotte O. Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis Rheum 2008, 58:1521-1527.
65. Zhao D.B., Dai S.M., Liu X.P., Xu H. Interstitial inflammation in visceral organs is a pathologic feature of adult-onset Still's disease. Rheumatol Int 2011, 31:923-927.
66. 18F-fluoro-dexoxyglucose positron emission tomography in patients with adult-onset Still's disease: report of two cases and review of literatures. Rheumatol Int 2010, 30:1673-1676.
67. Yamashita H., Kubota K., Takahashi Y., Minamimoto R., Morooka M., Kaneko H., et al. Clinical value of (18)F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still's disease: a seven-case series and review of the literature. Mod Rheumatol 2013, 24:645-650.
68. Yamaguchi M., Ohta A., Tsunematsu T., Kasukawa R., Mizushima Y., Kashiwagi H., et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992, 19:424-430.
69. Fautrel B., Zing E., Golmard J.-L., Le Moël G., Bissery A., Rioux C., et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore) 2002, 81:194-200.
70. Cush J.J., Medsger T.A., Christy W.C., Herbert D.C., Cooperstein L.A. Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum 1987, 30:186-194.
71. Wouters J.M., van de Putte L.B. Adult-onset Still's disease; clinical and laboratory features, treatment and progress of 45cases. Q J Med 1986, 61:1055-1065.
72. Arlet J.-B., Le T.H., Marinho A., Amoura Z., Wechsler B., Papo T., et al. Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature. Ann Rheum Dis 2006, 65:1596-1601.
73. Gerfaud-Valentin M., Sève P., Iwaz J., Gagnard A., Broussolle C., Durieu I., et al. Myocarditis in adult-onset Still disease. Medicine (Baltimore) 2014, 93:280-289.
74. Efthimiou P., Kadavath S., Mehta B. Life-threatening complications of adult-onset Still's disease. Clin Rheumatol 2014, 33:305-314.
75. Gerfaud-Valentin M., Hot A., Huissoud C., Durieu I., Broussolle C., Sève P. Adult-onset Still's disease and pregnancy: about ten cases and review of the literature. Rheumatol Int 2014, 34:867-871.
76. Dhote R., Simon J., Papo T., Detournay B., Sailler L., Andre M.-H., et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum 2003, 49:633-639.
77. Kong X.D., Xu D., Zhang W., Zhao Y., Zeng X., Zhang F. Clinical features and prognosis in adult-onset Still's disease: a study of 104cases. Clin Rheumatol 2010, 29:1015-1019.
78. Kim H.A., Sung J.M., Suh C.H. Therapeutic responses and prognosis in adult-onset Still's disease. Rheumatol Int 2012, 32:1291-1298.
79. Franchini S., Dagna L., Salvo F., Aiello P., Baldissera E., Sabbadini M.G. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. Arthritis Rheum 2010, 62:2530-2535.
80. Kim Y.J., Koo B.S., Kim Y.G., Lee C.K., Yoo B. Clinical features and prognosis in 82patients with adult-onset Still's disease. Clin Exp Rheumatol 2014, 32:28-33.
81. Fautrel B., Borget C., Rozenberg S., Meyer O., Le Loët X., Masson C., et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol 1999, 26:373-378.
82. Vignes S., Wechsler B., Amoura Z., Papo T., Francès C., Huong D.L., et al. Intravenous immunoglobulin in adult Still's disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 1998, 16:295-298.
83. Liozon E., Ly K., Aubard Y., Vidal E. Intravenous immunoglobulins for adult Still's disease and pregnancy. Rheumatology (Oxford) 1999, 38:1024-1025.
84. Cavagna L., Caporali R., Epis O., Bobbio-Pallavicini F., Montecucco C. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol 2001, 19:329-332.
85. Kraetsch H.G., Antoni C., Kalden J.R., Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 2001, 60(Suppl.3):55-57.
86. Kokkinos A., Iliopoulos A., Greka P., Efthymiou A., Katsilambros N., Sfikakis P.P. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol 2004, 23:45-49.
87. Husni M.E., Maier A.L., Mease P.J., Overman S.S., Fraser P., Gravallese E.M., et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002, 46:1171-1176.
88. Fautrel B., Sibilia J., Mariette X., Combe B. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20cases. Ann Rheum Dis 2005, 64:262-266. Club rhumatisme et inflammation.
89. Kaneko K., Kaburaki M., Muraoka S., Tanaka N., Yamamoto T., Kusunoki Y., et al. Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration. Int J Rheum Dis 2010, 13:67-69.
90. Agarwal S., Moodley J., Ajani Goel G., Theil K.S., Mahmood S.S., Lang R.S. A rare trigger for macrophage activation syndrome. Rheumatol Int 2011, 31:405-407.
91. Rudinskaya A., Trock D.H. Successful treatment of a patient with refractory adult-onset still disease with anakinra. J Clin Rheumatol 2003, 9:330-332.
92. Fitzgerald A.A., Leclercq S.A., Yan A., Homik J.E., Dinarello C.A. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005, 52:1794-1803.
93. Kalliolias G.D., Georgiou P.E., Antonopoulos I.A., Andonopoulos A.P., Liossis S.N. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 2007, 66:842-843.
94. Kötter I., Wacker A., Koch S., Henes J., Richter C., Engel A., et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 2007, 37:189-197.
95. Giampietro C., Ridene M., Lequerre T., Costedoat Chalumeau N., Amoura Z., Sellam J., et al. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res 2013, 65:822-826.
96. Moulis G., Sailler L., Astudillo L., Pugnet G., Arlet P. May anakinra be used earlier in adult onset Still disease?. Clin Rheumatol 2010, 29:1199-1200.
97. Nigrovic P.A., Mannion M., Prince F.H.M., Zeft A., Rabinovich C.E., van Rossum M.A.J., et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011, 63:545-555.
98. DeWitt E.M., Kimura Y., Beukelman T., Nigrovic P.A., Onel K., Prahalad S., et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res 2012, 64:1001-1010.
99. Laskari K., Tzioufas A.G., Moutsopoulos H.M. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Res Ther 2011, 13:91.
100. Nordström D., Knight A., Luukkainen R., van Vollenhoven R., Rantalaiho V., Kajalainen A., et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol 2012, 39:2008-2011.
101. Puéchal X., DeBandt M., Berthelot J.-M., Breban M., Dubost J.-J., Fain O., et al. Tocilizumab in refractory adult Still's disease. Arthritis Care Res 2011, 63:155-159.
102. Cipriani P., Ruscitti P., Carubbi F., Pantano I., Liakouli V., Berardicurti O., et al. Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. Clin Rheumatol 2013, 33:49-55.
103. Elkayam O., Jiries N., Dranitzki Z., Kivity S., Lidar M., Levy O., et al. Tocilizumab in adult-onset Still's disease: the Israeli experience. J Rheumatol 2014, 41:244-247.
104. Ortiz-Sanjuán F., Blanco R., Calvo-Rio V., Narvaez J., Rubio Romero E., Olivé A., et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 2014, 66:1659-1665.
105. De Benedetti F., Brunner H.I., Ruperto N., Kenwright A., Wright S., Calvo I., et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367:2385-2395.
106. Pouchot J., Arlet J.B. Biological treatment in adult-onset Still's disease. Best Pract Res Clin Rheumatol 2012, 26:477-487.
107. Shimizu M., Nakagishi Y., Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 2013, 61:345-348.
108. Shimizu M., Yokoyama T., Yamada K., Kaneda H., Wada H., Wada T., et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 2010, 49:1645-1653.
109. Ichida H., Kawaguchi Y., Sugiura T., Takagi K., Katsumata Y., Gono T., et al. Clinical manifestations of adult-onset still's disease presenting with erosive arthritis: association with low levels of ferritin and IL-18. Arthritis Care Res 2013, [Epub ahead of print]. 10.1002/acr.22194.
110. Canna S.W. Editorial: interferon-γ: friend or foe in systemic juvenile idiopathic arthritis and adult-onset Still's disease?. Arthritis Rheumatol 2014, 66:1072-1076.